Ligand Pharmaceuticals LGND Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's total equity?
- Ligand Pharmaceuticals (LGND) reported total equity of $997.32M in Q1 2026.
- How has Ligand Pharmaceuticals's total equity changed year-over-year?
- Ligand Pharmaceuticals's total equity increased by 25.4% year-over-year, from $795.59M to $997.32M.
- What is the long-term trend for Ligand Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's total equity has grown at a 7.5% compound annual growth rate (CAGR), from $709.53M to $1.02B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.